341 related articles for article (PubMed ID: 34942189)
1. Organoids as research models for hepatocellular carcinoma.
Yu JH; Ma S
Exp Cell Res; 2022 Feb; 411(1):112987. PubMed ID: 34942189
[TBL] [Abstract][Full Text] [Related]
2. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.
Broutier L; Mastrogiovanni G; Verstegen MM; Francies HE; Gavarró LM; Bradshaw CR; Allen GE; Arnes-Benito R; Sidorova O; Gaspersz MP; Georgakopoulos N; Koo BK; Dietmann S; Davies SE; Praseedom RK; Lieshout R; IJzermans JNM; Wigmore SJ; Saeb-Parsy K; Garnett MJ; van der Laan LJ; Huch M
Nat Med; 2017 Dec; 23(12):1424-1435. PubMed ID: 29131160
[TBL] [Abstract][Full Text] [Related]
3. Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance.
Liu J; Li P; Wang L; Li M; Ge Z; Noordam L; Lieshout R; Verstegen MMA; Ma B; Su J; Yang Q; Zhang R; Zhou G; Carrascosa LC; Sprengers D; IJzermans JNM; Smits R; Kwekkeboom J; van der Laan LJW; Peppelenbosch MP; Pan Q; Cao W
Cell Mol Gastroenterol Hepatol; 2021; 11(2):407-431. PubMed ID: 32932015
[TBL] [Abstract][Full Text] [Related]
4. Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids.
Wang S; Wang Y; Xun X; Zhang C; Xiang X; Cheng Q; Hu S; Li Z; Zhu J
J Exp Clin Cancer Res; 2020 Jan; 39(1):22. PubMed ID: 31992334
[TBL] [Abstract][Full Text] [Related]
5. Plasma-derived extracellular matrix for xenofree and cost-effective organoid modeling for hepatocellular carcinoma.
El-Derby AM; Khedr MA; Ghoneim NI; Gabr MM; Khater SM; El-Badri N
J Transl Med; 2024 May; 22(1):487. PubMed ID: 38773585
[TBL] [Abstract][Full Text] [Related]
6. Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies.
Nuciforo S; Fofana I; Matter MS; Blumer T; Calabrese D; Boldanova T; Piscuoglio S; Wieland S; Ringnalda F; Schwank G; Terracciano LM; Ng CKY; Heim MH
Cell Rep; 2018 Jul; 24(5):1363-1376. PubMed ID: 30067989
[TBL] [Abstract][Full Text] [Related]
7. Updates on Organoid Model for the Study of Liver Cancer.
El-Khobar KE; Sukowati CHC
Technol Cancer Res Treat; 2023; 22():15330338231154090. PubMed ID: 36788421
[TBL] [Abstract][Full Text] [Related]
8. YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation.
Cho K; Ro SW; Lee HW; Moon H; Han S; Kim HR; Ahn SH; Park JY; Kim DY
Hepatology; 2021 Nov; 74(5):2605-2621. PubMed ID: 34101869
[TBL] [Abstract][Full Text] [Related]
9. Liver Organoids as an In Vitro Model to Study Primary Liver Cancer.
De Siervi S; Turato C
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901961
[TBL] [Abstract][Full Text] [Related]
10. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
11. The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy.
Guan Y; Chen X; Wu M; Zhu W; Arslan A; Takeda S; Nguyen MH; Majeti R; Thomas D; Zheng M; Peltz G
J Hepatol; 2020 Apr; 72(4):746-760. PubMed ID: 31760071
[TBL] [Abstract][Full Text] [Related]
12. Organoid technology in cancer precision medicine.
Xia X; Li F; He J; Aji R; Gao D
Cancer Lett; 2019 Aug; 457():20-27. PubMed ID: 31078736
[TBL] [Abstract][Full Text] [Related]
13. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.
Abugomaa A; Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Mori T; Uchide T; Azakami D; Fukushima R; Yoshida T; Shibutani M; Yamashita R; Kobayashi M; Yamawaki H; Shinohara Y; Kaneda M; Usui T; Sasaki K
Sci Rep; 2020 Jun; 10(1):9393. PubMed ID: 32523078
[TBL] [Abstract][Full Text] [Related]
14. Personalized therapy for hepatocellular carcinoma: Where are we now?
Chan SL; Wong AM; Lee K; Wong N; Chan AK
Cancer Treat Rev; 2016 Apr; 45():77-86. PubMed ID: 26995632
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers.
Li L; Selaru FM
Adv Cancer Res; 2022; 156():319-341. PubMed ID: 35961704
[TBL] [Abstract][Full Text] [Related]
16. Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery.
Zhang CY; Zhang XF; Yuan J; Gong YF; Tang H; Guo WY; Li TY; Li CW; Tang YQ; Ma NF; Liu M
J Vis Exp; 2023 Aug; (198):. PubMed ID: 37607105
[TBL] [Abstract][Full Text] [Related]
17. Human liver cancer organoids: Biological applications, current challenges, and prospects in hepatoma therapy.
Chen L; Wei X; Gu D; Xu Y; Zhou H
Cancer Lett; 2023 Feb; 555():216048. PubMed ID: 36603689
[TBL] [Abstract][Full Text] [Related]
18. Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine.
Qu S; Xu R; Yi G; Li Z; Zhang H; Qi S; Huang G
Mol Biomed; 2024 Feb; 5(1):6. PubMed ID: 38342791
[TBL] [Abstract][Full Text] [Related]
19. Mini-organs with big impact: Organoids in liver cancer studies.
Khawar MB; Wang Y; Majeed A; Afzal A; Haneef K; Sun H
Oncol Res; 2023; 31(5):677-688. PubMed ID: 37547759
[TBL] [Abstract][Full Text] [Related]
20. Ter-cell, A New Target for Hepatocellular Carcinoma Therapy.
Cen X; Cheng K
Chembiochem; 2018 Nov; 19(21):2254-2256. PubMed ID: 30136761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
